Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. (Q33884461)

29 July 2017

title

Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. (English)

1 reference

29 July 2017

1 reference

Jane K Sosabowski

8

0 references

Meltem Ocak

object named as

Meltem Ocak

1

0 references

Clemens Decristoforo

object named as

Clemens Decristoforo

11

0 references

Jean Claude Reubi

10

object named as

Jean Claude Reubi

1 reference

29 July 2017

Anna Helbok

2

1 reference

29 July 2017

Christine Rangger

3

1 reference

29 July 2017

Petra Kolenc Peitl

4

1 reference

29 July 2017

Berthold A Nock

5

1 reference

29 July 2017

Giancarlo Morelli

6

1 reference

29 July 2017

Annemarie Eek

7

1 reference

29 July 2017

Wout A P Breeman

9

1 reference

29 July 2017

publication date

29 April 2011

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

29 July 2017

published in

1 reference

29 July 2017

volume

38

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

1426-1435

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-011-1818-9

29 July 2017

exact match

0 references

cites work

Radiolabelled regulatory peptides for imaging and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Peptide-based probes for cancer imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Development and clinical application of peptide-based radiopharmaceuticals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Strategies to improve plasma half life time of peptide and protein drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Converting a peptide into a drug: strategies to improve stability and bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Ectoenzymes as sites of peptide regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Degradation of human gastrin and CCK by endopeptidase 24.11: differential behaviour of the sulphated and unsulphated peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Phenethyl ester derivative analogs of the C-terminal tetrapeptide of gastrin as potent gastrin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1818-9

Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.

21 January 2018

1 reference

12 December 2020

CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.

1 reference

12 December 2020

Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors

1 reference

12 December 2020

The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates

1 reference

12 December 2020

In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging

1 reference

12 December 2020

10.1007/S00259-011-1818-9

Identifiers

DOI

1 reference

29 July 2017

1 reference